Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Annnnd there goes the technicals.
Great report. Should be up 6%
No idea but man what a beating they're taking. Down 10% good grief.
Yes it's on my watchlist. The concern I believe is that is LUV is guiding down, it poses AAL risk. Which is absurd seeing how AAL has been doing fairly well last couple reports. Dal guided up as well.
Thank you. Great stuff!
Hey bright side is now AAL can pass LUV in pps again as money flows out haha.
So DAL guides UP, and LUV guides down? Interesting
Could have sworn they guided down to flat last time. Could be wrong.
Picked up day trade shares $46.80 for a gamble on a recovery.
LUV hit $46.77 = strong buy for a flip
LUV had a fantastic report I can't see why they're down so much.
I was extremely disappointed. Boring predictable play calling. Need to air the ball out way more. Should have won that game easily with all those turnovers.
Southwest Airlines Reports November Traffic
Source: PR Newswire (US)
DALLAS, Dec. 8, 2015 /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) (the "Company") today reported its November and year-to-date preliminary traffic statistics. The Company flew 9.7 billion revenue passenger miles (RPMs) in November 2015, a 13.9 percent increase from the 8.6 billion RPMs flown in November 2014. Available seat miles (ASMs) increased 9.7 percent to 11.7 billion in November 2015, compared with the November 2014 level of 10.7 billion. The November 2015 load factor was a record for the month of November at 83.2 percent, compared with 80.1 percent in November 2014. Based on these results and current trends, the Company estimates its fourth quarter 2015 operating revenue per ASM (RASM) will be approximately flat to down 1.0 percent, compared with fourth quarter 2014.
Eagle Pharmaceuticals Achieves Milestone to Receive $15 Million Payment for Approval of BENDEKA
Source: Business Wire
-The Company will receive a 20% royalty on net sales of BENDEKA-
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) announced that it has achieved the milestone which entitles the Company to receive a $15 million payment from Teva Pharmaceuticals Industries Ltd. resulting from the U.S. Food and Drug Administration (“FDA”) approval of BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
The Company will receive a 20% royalty on net sales of BENDEKA. In addition, Eagle may earn an incremental step-up royalty upon the achievement of future milestones.
“We look forward to Teva’s successful commercialization of this new treatment option. We believe the $15 million milestone payment triggered by approval, coupled with future royalties of 20% on Teva’s net sales of BENDEKA, will expedite Eagle’s ability to deliver long-term, sustainable growth,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.
BENDEKA was granted Orphan Drug Designations for both CLL and indolent B-cell NHL.
Under the February 2015 exclusive license agreement for BENDEKA, Teva is responsible for all U.S. commercial activities for the product including promotion and distribution.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as “will,” “may,” “intends,” “anticipate(s),” “plan,” “enables,” “potentially,” “entitles,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events including, but not limited to: ADD IN HERE; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; and other factors that are discussed in Eagle’s Annual Report on Form 10-K for the year ended September 30, 2014, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to risks described in Eagle’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151208005841/en/
For Eagle Pharmaceuticals, Inc.:
In-Site Communications, Inc.
Lisa M. Wilson, 212-452-2793
President
Purely a money scheme here. Damn shame what they did with this. They weren't kidding a year ago when they called this a $15 stock. Sure as shit here it is...
Nick and his old Daddy made out like bandits.
All hail Redskins tonight! I'll be on the skins sidelines tonight.
Q2 2036 at this rate
This year, which is only a few more weeks, I see the ceiling around $27-$28 TOPS. Like you stated, carriers like SAVE have the type of upside that we just saw ALK go to (over $80+). ALK was trading where UAL is trading not long ago. HA, SAVE, VA have big upside 2016. JBLU had top dog this year and has run up a lot.
Prob won't get one for a while. Too much good news coming out left and right.
Nice 5%
What a great time for the sector!
I think I'm just glad that OPEC meeting saved the sector from a further drop today. This was certain to be around $42.70-$43 per options. Now the we know oil is headed to sub $30 the sector should be booming.
Hey to be fair, I'll take 2.8% green and a close over $44 all day long bro.
Save long way up..
OPEC not cutting production is the reason FYI
2 weeks
Hey I don't ask questions I just take it for what it is haha.
Sector looking great today
SAVE!
Way to buy the bottom! #winning
It's not done, but upside is limited with these analysts. $30 may be the ceiling. I still hold a big core though. SAVE on the other hand hit $85 earlier this year, and most recently $32 low. Highest upside IMO. It will do in 2016 what JBLU did in 2015. 2016 I like SAVE, VA, HA.
Curious to see if $42.70 holds tomorrow for a pin at $43...
Green in a sea of Red
Indeed!
Only carrier holding strong
$SAVE
Made more money on this in 2 weeks than POS AAL all year. Sad case..
I see 50-75% gain 2016 at least from here.
$85 stock trading near the 52 week low...all upside
2016 SAVE, HA, VA. All 3 will hawk the legacy carriers in pps.
Oh and to answer your question we need to break and hold some technicals